Your browser doesn't support javascript.
loading
Potent transmission-blocking monoclonal antibodies from naturally exposed individuals target a conserved epitope on Plasmodium falciparum Pfs230.
Ivanochko, Danton; Fabra-García, Amanda; Teelen, Karina; van de Vegte-Bolmer, Marga; van Gemert, Geert-Jan; Newton, Jocelyn; Semesi, Anthony; de Bruijni, Marloes; Bolscher, Judith; Ramjith, Jordache; Szabat, Marta; Vogt, Stefanie; Kraft, Lucas; Duncan, Sherie; Lee, Shwu-Maan; Kamya, Moses R; Feeney, Margaret E; Jagannathan, Prasanna; Greenhouse, Bryan; Sauerwein, Robert W; Richter King, C; MacGill, Randall S; Bousema, Teun; Jore, Matthijs M; Julien, Jean-Philippe.
Afiliación
  • Ivanochko D; Program in Molecular Medicine, the Hospital for Sick Children Research Institute, Toronto, ON, Canada.
  • Fabra-García A; Department of Medical Microbiology, Radboudumc, Nijmegen, the Netherlands.
  • Teelen K; Department of Medical Microbiology, Radboudumc, Nijmegen, the Netherlands.
  • van de Vegte-Bolmer M; Department of Medical Microbiology, Radboudumc, Nijmegen, the Netherlands.
  • van Gemert GJ; Department of Medical Microbiology, Radboudumc, Nijmegen, the Netherlands.
  • Newton J; Program in Molecular Medicine, the Hospital for Sick Children Research Institute, Toronto, ON, Canada.
  • Semesi A; Program in Molecular Medicine, the Hospital for Sick Children Research Institute, Toronto, ON, Canada.
  • de Bruijni M; TropIQ Health Sciences, Nijmegen, the Netherlands.
  • Bolscher J; TropIQ Health Sciences, Nijmegen, the Netherlands.
  • Ramjith J; Radboud Institute for Health Sciences, Department for Health Evidence, Biostatistics Section, Radboudumc, Nijmegen, the Netherlands.
  • Szabat M; AbCellera Biologics Inc., Vancouver, BC, Canada.
  • Vogt S; AbCellera Biologics Inc., Vancouver, BC, Canada.
  • Kraft L; AbCellera Biologics Inc., Vancouver, BC, Canada.
  • Duncan S; AbCellera Biologics Inc., Vancouver, BC, Canada.
  • Lee SM; PATH's Malaria Vaccine Initiative, Washington, DC 20001, USA.
  • Kamya MR; Infectious Disease Research Collaboration, Kampala, Uganda.
  • Feeney ME; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
  • Jagannathan P; Department of Microbiology and Immunology, Stanford University, Stanford, CA, USA.
  • Greenhouse B; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Sauerwein RW; TropIQ Health Sciences, Nijmegen, the Netherlands.
  • Richter King C; PATH's Malaria Vaccine Initiative, Washington, DC 20001, USA.
  • MacGill RS; PATH's Malaria Vaccine Initiative, Washington, DC 20001, USA.
  • Bousema T; Department of Medical Microbiology, Radboudumc, Nijmegen, the Netherlands. Electronic address: teun.bousema@radboudumc.nl.
  • Jore MM; Department of Medical Microbiology, Radboudumc, Nijmegen, the Netherlands. Electronic address: matthijs.jore@radboudumc.nl.
  • Julien JP; Program in Molecular Medicine, the Hospital for Sick Children Research Institute, Toronto, ON, Canada; Departments of Biochemistry and Immunology, University of Toronto, Toronto, ON, Canada. Electronic address: jean-philippe.julien@sickkids.ca.
Immunity ; 56(2): 420-432.e7, 2023 02 14.
Article en En | MEDLINE | ID: mdl-36792575
Pfs230 is essential for Plasmodium falciparum transmission to mosquitoes and is the protein targeted by the most advanced malaria-transmission-blocking vaccine candidate. Prior understanding of functional epitopes on Pfs230 is based on two monoclonal antibodies (mAbs) with moderate transmission-reducing activity (TRA), elicited from subunit immunization. Here, we screened the B cell repertoire of two naturally exposed individuals possessing serum TRA and identified five potent mAbs from sixteen Pfs230 domain-1-specific mAbs. Structures of three potent and three low-activity antibodies bound to Pfs230 domain 1 revealed four distinct epitopes. Highly potent mAbs from natural infection recognized a common conformational epitope that is highly conserved across P. falciparum field isolates, while antibodies with negligible TRA derived from natural infection or immunization recognized three distinct sites. Our study provides molecular blueprints describing P. falciparum TRA, informed by contrasting potent and non-functional epitopes elicited by natural exposure and vaccination.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Malaria Falciparum / Vacunas contra la Malaria Límite: Animals / Humans Idioma: En Revista: Immunity Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Malaria Falciparum / Vacunas contra la Malaria Límite: Animals / Humans Idioma: En Revista: Immunity Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Canadá